Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: twomail compared to Larscot ...

Apparently, you do not understand the dynamics of this situation. Your logic is sound, but it applies to a company with an established product, allowing for sustained revs.

The PTSC CEO is in virtual decision limbo until the validity of the patents (and their long-term value) can be established. Their short-term fate rests squarely in the hands of TPL and the signings they can generate. Long-term rev potentials of any factor rest with the outcome of the USPTO rulings, Period.

Their ultimate long-term fate (related to sustained reveunues at multiple factors above the present) rests in the hands of the USPTO.

The Market understand this. We should also.

Regards

Share
New Message
Please login to post a reply